Nebenwirkungen · Tarceva
Tarceva 25 mg film-coated tablets Tarceva 100 mg film-coated tablets Tarceva 150 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 9
HOS-114499 · Präparat HOS-094097
Tabulated summary of adverse reactions The incidence of ADRs from clinical trials and the post marketing setting reported with Tarceva alone or in combination with chemotherapy are summarised in Table 1. Adverse drug reactions are listed by MedDRA system organ class. The corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-05T14:10:00Z · SHA-256 4f9c738a5861ce6d74c31277709e30968e275c29015450902926409dd5330a31 · Passage 0d7c61dc1fe3d2d991f2a3cac2758bfdf5dff4d9dd6a888dfeb6dd033a09f368 · Zeichen 2139–2700 im Abschnitt